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Editorial on the Research Topic
Gene Silencing and Editing Strategies for Neurodegenerative Diseases
The discovery of the RNA interference (RNAi) mechanism and the development of gene editing
techniques such as TALENs or CRISPR/Cas9 opened a new avenue for the treatment and
understanding of neurodegenerative diseases. If the main goal and most straightforward rationale
is to use these systems to develop therapeutic options for neurodegenerative diseases, it is also clear
that RNAi and editing strategies are valuable for research, as tools for the understanding of the
molecular mechanisms implicated in these diseases or, alternatively, to develop research models for
their study.
Recent studies have demonstrated that several biological networks implicated in the modulation
of gene expression at transcriptional, post-transcriptional and epigenetic levels, are tightly
regulated by multiple long non-coding RNAs (lncRNAs), some of them specifically expressed
in the central nervous system (CNS). These lncRNAs may have an important role in the
pathophysiology of neurodegenerative diseases. So far, deregulation of most lncRNAs is widely
associated to the progression of neurodegenerative disorders like Alzheimer’s (AD), Parkinson’s
(PD), and Huntington’s (HD) diseases, as well as Amyotrophic Lateral Sclerosis (ALS). Quan
et al. comprehensively discuss several lncRNAs-associated regulatory mechanisms, which may be
involved in the pathophysiology of the above-mentioned diseases. They conclude that additional
investigation of lncRNAs rolls has the potential to achieve increasing insights about their functions
and therefore to better engineer therapeutic strategies based on lncRNAs modulation.
SILENCING AND EDITING STRATEGIES AS THERAPEUTIC
APPROACHES
Recently, the toxicity at the RNA level emerged as a new important player in the pathogenesis of HD
and other Polyglutamine (polyQ) disorders. Several studies have demonstrated cell degeneration
and dysfunction associated to the expression of untranslated transcripts with expanded CAG
repeats. Therefore, the development of editing strategies provided the tools and opportunity to
directly target the mutant gene, thus preventing the formation of toxic RNA and the consequent
cascade of pathological events. In line with this idea, Dabrowska et al. developed a CRISPR/Cas9
strategy based in the precise excision of the CAG tract using derived fibroblasts from several HD
patients. This strategy was successful in excising the repeats leading to a safe and specific abolition
of huntingtin synthesis. These important results if translated to in vivo studies could become a
therapeutic option in future clinical trials for HD patients.
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Another gene silencing-based therapy is the use of
antisense oligonucleotides delivered by calcium-phosphate-
lipid nanoparticles. The goal is to lower mutant superoxide
dismutase I (SOD1), that abnormally accumulates in ALS motor
neurons. Thus, SOD1 lowering could be an effective therapeutic
strategy. To circumvent the short half-life of ASOs and the
fact that they cannot cross the blood-brain-barrier, Chen et al.
propose calcium phosphate lipid coated nanoparticles-based
delivery of ASOs targeting SOD1 in motor neurons, as an
effective and safe delivery system to the CNS. The authors also
report for the first time the distribution of nanoparticles in the
brain and spinal cord of zebrafish, a powerful animal model to
develop therapies for ALS and other neurological disorders.
SILENCING AND EDITING STRATEGIES AS
RESEARCH TOOL
To Understand the Molecular Mechanisms
Underlying Neuronal Events
Methamphetamine (METH) is a stimulant drug that induce
toxicity in the CNS, especially in dopaminergic neurons.
Du et al. explored the effect of METH in astrocyte-related
neuroinflammation, using siRNAs to block the expression of
Caspase-11 and toll-like receptor (TLR4) in primary cultures of
mouse astrocytes. They found that siRNA inhibition of Caspase-
11 reduce the expression of pro-inflammatory cytokines, whereas
TLR4 inhibition decrease the METH-induced activation of
NF-kB and Caspse-11. These results highlight the importance of
both Caspase-11 and TLR4 in the neuroinflammation induced by
METH.
Inflammation is induced upon cerebral ischemia, with an
activation of microglia and their phenotype alteration to M1 or
M2, depending on the microenvironment stimuli. The study by
Cheon et al. use siRNA-based strategies to study the involvement
of signal-regulating kinase 1 (ASK1) in microglia function and
its alterations upon ischemic stroke. The results show that
ASK1 inhibition suppressed the expression of M1-associated
genes (pro-inflammatory mediators), whereas augmented M2-
associated genes expression (anti-inflammatory mediators). The
authors propose that ASK1 modulation might constitute a new
strategy for repair, targeting the microglia phenotype after an
ischemic stroke.
Cholesterol metabolism has been widely associated to
several neurodegenerative diseases including Alzheimer’s disease.
Despite this, lipid modifications associated to the disease
progression, as well as the link between altered cholesterol
levels and AD still remains poorly understood. In Ayciriex
et al. the authors promoted the silencing of the Cyp46a1 gene
(which encodes the cholesterol 24-hydroxylase) in the mouse
hippocampus and performed both targeted and non-targeted
approaches by liquid chromatography coupled to high resolution
mass spectroscopy to better understand lipid modifications
associated to AD-like degeneration. The authors show that the
cholesterol 24-hydroxylase silencing, key enzyme in cholesterol
metabolism deregulates lipid homeostasis in brain, thus allowing
dissecting the role of cholesterol metabolism in AD and other
neurodegenerative diseases.
Mitochondrial dysfunction underlies the pathogenesis of
several neurodegenerative diseases, including PD. Ye et al.
use the RNAi pathway to inhibit peroxisome proliferator-
activated receptor γ coactivator-1alpha (PGC-1α) in a PD cellular
model. PGC-1α is implicated in the regulation of mitochondrial
biogenesis and oxidative capacity. The use of siRNAs reducing
the levels of PGC-1α led to a reduction of mitochondrial
membrane potential, intracellular ATP content and intracellular
H2O2 generation, thus establishing PGC-1α as an important
modulator of mitochondria function.
In summary, all these studies highlight the importance of gene
silencing strategies to achieve a better understanding of biological
cellular mechanistic pathways.
To Develop Research Models
The development of research models is an essential tool
for studying the molecular and cellular events underlying
a pathogenesis and for testing new therapeutic approaches.
Induced pluripotent stem cells (iPSCs), became one of the
most popular research models, providing the opportunity to
have customized models for diseases and patients. Szlachcic
et al. developed a study aiming the development of HD
iPS cells, where huntingtin was silenced by shRNAs. The
authors achieved a stable silencing of huntingtin in different
HD iPSc lines, remaining active until the differentiation in
neural stem cells. The authors used the developed model
to study the effect of huntingtin silencing in different
signaling pathways, providing evidences for usefulness of
the model to study the molecular processes underlying HD
pathogenesis.
All these studies highlight that gene silencing and editing
tools are powerful tools for research, allowing the development
of advanced therapies based in gene and cell delivery, and
importantly allowing the modulation of cellular pathways and
functions as well as to develop new models to be used for
research.
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